Literature DB >> 33538817

Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan.

Tomohiro Takano1, Takayuki Matsumura1, Yu Adachi1, Kazutaka Terahara1, Saya Moriyama1, Taishi Onodera1, Ayae Nishiyama1, Ai Kawana-Tachikawa2, Shoji Miki2, Kaori Hosoya-Nakayama2, Midori Nakamura-Hoshi2, Sayuri Seki2, Natsuo Tachikawa3, Yukihiro Yoshimura3, Nobuyuki Miyata3, Hiroshi Horiuchi3, Hiroaki Sasaki3, Kazuhito Miyazaki3, Noriko Kinoshita4, Tsutomu Sudo4, Yutaro Akiyama4, Rubuna Sato4, Tadaki Suzuki5, Tetsuro Matano2, Yoshimasa Takahashi1.   

Abstract

An expanded myeloid cell compartment is a hallmark of severe coronavirus disease 2019 (COVID-19). However, data regarding myeloid cell expansion have been collected in Europe, where the mortality rate by COVID-19 is greater than those in other regions including Japan. Thus, characteristics of COVID-19-induced myeloid cell subsets remain largely unknown in the regions with low mortality rates. Here, we analyzed cellular dynamics of myeloid-derived suppressor cell (MDSC) subsets and examined whether any of them correlate with disease severity and prognosis, using blood samples from Japanese COVID-19 patients. We observed that polymorphonuclear (PMN)-MDSCs, but not other MDSC subsets, transiently expanded in severe cases but not in mild or moderate cases. Contrary to previous studies in Europe, this subset selectively expanded in survivors of severe cases and subsided before discharge, but such transient expansion was not observed in non-survivors in Japanese cohort. Analysis of plasma cytokine/chemokine levels revealed positive correlation of PMN-MDSC frequencies with IL-8 levels, indicating the involvement of IL-8 on recruitment of PMN-MDSCs to peripheral blood following the onset of severe COVID-19. Our data indicate that transient expansion of the PMN-MDSC subset results in improved clinical outcome. Thus, this myeloid cell subset may be a predictor of prognosis in cases of severe COVID-19 in Japan. © The Japanese Society for Immunology. 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  SARS-CoV-2; chemokine; cytokine; innate immunity; myeloid-derived suppressor cell

Mesh:

Substances:

Year:  2021        PMID: 33538817      PMCID: PMC7928855          DOI: 10.1093/intimm/dxab005

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  12 in total

Review 1.  Role of T Regulatory Cells and Myeloid-Derived Suppressor Cells in COVID-19.

Authors:  Alhasan Alsalman; Mohammad A Al-Mterin; Eyad Elkord
Journal:  J Immunol Res       Date:  2022-04-19       Impact factor: 4.493

Review 2.  Myeloid-derived suppressor cells in COVID-19: A review.

Authors:  Yuliya V Perfilyeva; Yekaterina O Ostapchuk; Raikhan Tleulieva; Aykin Kali; Nurshat Abdolla; Vladimir K Krasnoshtanov; Anastassiya V Perfilyeva; Nikolai N Belyaev
Journal:  Clin Immunol       Date:  2022-04-27       Impact factor: 10.190

3.  I-FABP is decreased in COVID-19 patients, independently of the prognosis.

Authors:  Kevin Guedj; Mathieu Uzzan; Damien Soudan; Catherine Trichet; Antonino Nicoletti; Emmanuel Weiss; Hana Manceau; Alexandre Nuzzo; Olivier Corcos; Xavier Treton; Katell Peoc'h
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

Review 4.  Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19.

Authors:  Toshifumi Matsuyama; Steven K Yoshinaga; Kimitaka Shibue; Tak W Mak
Journal:  Cell Death Differ       Date:  2021-10-18       Impact factor: 15.828

5.  Correlation of myeloid-derived suppressor cells with C-reactive protein, ferritin and lactate dehydrogenase levels in patients with severe COVID-19.

Authors:  Ayca Emsen; Sua Sumer; Baykal Tulek; Hilal Cizmecioglu; Husamettin Vatansev; Mevlut Hakan Goktepe; Fikret Kanat; Yavuz Koksal; Ugur Arslan; Hasibe Artac
Journal:  Scand J Immunol       Date:  2021-10-15       Impact factor: 3.889

6.  Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19.

Authors:  Carlos Jiménez-Cortegana; Flora Sánchez-Jiménez; Antonio Pérez-Pérez; Nerissa Álvarez; Alberto Sousa; Luisa Cantón-Bulnes; Teresa Vilariño-García; Sandra Fuentes; Salomón Martín; Marta Jiménez; Antonio León-Justel; Luis de la Cruz-Merino; José Garnacho-Montero; Víctor Sánchez-Margalet
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

Review 7.  New Discovery of Myeloid-Derived Suppressor Cell's Tale on Viral Infection and COVID-19.

Authors:  Soo-Jeung Park; Da-Eun Nam; Hae Chang Seong; Young S Hahn
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

8.  Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation.

Authors:  Alok K Singh; Rulin Wang; Kara A Lombardo; Monali Praharaj; C Korin Bullen; Peter Um; Stephanie Davis; Oliver Komm; Peter B Illei; Alvaro A Ordonez; Melissa Bahr; Joy Huang; Anuj Gupta; Kevin J Psoter; Sanjay K Jain; Trinity J Bivalacqua; Srinivasan Yegnasubramanian; William R Bishai
Journal:  bioRxiv       Date:  2022-03-15

Review 9.  Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes.

Authors:  Jacopo Sabbatinelli; Giulia Matacchione; Angelica Giuliani; Deborah Ramini; Maria Rita Rippo; Antonio Domenico Procopio; Massimiliano Bonafè; Fabiola Olivieri
Journal:  Mech Ageing Dev       Date:  2022-03-25       Impact factor: 5.498

Review 10.  Myeloid-Derived Suppressor Cells as a Potential Biomarker and Therapeutic Target in COVID-19.

Authors:  Marianna Rowlands; Florencia Segal; Dominik Hartl
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.